Slice me nice: DNAzymes get close to the heart

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1476-1478

  Kelley, R ^a   Patterson, Cam ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOZYME; ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBOZYME; DNAZYME; EARLY GROWTH RESPONSE FACTOR 1; FOMIVIRSEN; LIPID; MESSENGER RNA; NUCLEIC ACID; OLIGONUCLEOTIDE; POLYMER; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

BINDING AFFINITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; GENE TARGETING; GENE THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; MEMBRANE TRANSPORT; NONHUMAN; NOTE; PRIORITY JOURNAL; REPERFUSION INJURY; RETINITIS; RNA CLEAVAGE;

ANIMALS; DNA, CATALYTIC; HUMANS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RNA, ANTISENSE;

EID: 33745235528     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02034.x     Document Type: Note

References (20)

1. Bhindi R, Khachigian LM, Lowe HC. DNAzymes targeting the transcription factor EGR-1 reduce myocardial infart size following ischemia-reperfusion in rats. J Thromb Haemost 2006; 4: 1479-83.
2. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-6.
3. Kurreck J, Bieber B, Jahnel R, Erdmann VA. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem 2002; 277: 7099-107.
4. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
5. Schubert S, Furste JP, Werk D, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J. Gaining target access for deoxyribozymes. J Mol Biol 2004; 339: 355-63.
6. Zaborowska Z, Schubert S, Kurreck J, Erdmann VA. Deletion analysis in the catalytic region of the 10-23 DNA enzyme. FEBS Lett 2005; 579: 554-8.
7. Sioud M, Leirdal M. Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application. J Mol Biol 2000; 296: 937-47.
8. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun LQ. Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 1999; 17: 480-6.
9. Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S. Gene silencing nucleic acids designed by scanning arrays: Anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target 2003; 11: 449-56.
10. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: A comprehensive review. Aaps J 2005; 7: E61-77.
11. Dass CR. Preclinical anticancer activity of DNA-based cleavage molecules. Drug Dev Ind Pharm 2006; 32: 1-5.
12. Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther 1999; 10: 2847-57.
13. Pan WH, Clawson GA. Antisense applications for biological control. J Cell Biochem 2006; 98: 14-35.
14. Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res 2000; 62: 5463-69.
15. Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG, Khachigian LM. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999; 5: 1264-69.
16. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003; 9: 1026-32.
17. Sandberg JA, Parker VP, Blanchard KS, Sweedler D, Powell JA, Kachensky A, Bellon L, Usman N, Rossing T, Borden E, Blatt LM. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J Clin Pharmacol 2000; 40: 1462-9.
18. Parry TJ, Bouhana KS, Blanchard KS, Pavco PA, Sandberg JA. Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens. Curr Issues Mol Biol 2000; 2: 113-8.
19. Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005; 56: 329-36.
20. Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998; 4: 14-6.